Articles tagged with Drug Therapy
Women with catamenial epilepsy experience nearly four times more frequent seizures during menstrual cycle and are more likely to have drug-resistant epilepsy. The study may lead to tailored treatments for this group.
A recent Italian observational study reveals that hydroxychloroquine treatment reduces the risk of death for hospitalized COVID-19 patients by 30%. The study, coordinated by I.R.C.C.S. Neuromed, analyzed data from 3,451 patients and found positive results despite using lower doses than those in other countries.
Researchers have developed a simple, low-cost technology for subcutaneous injection of viscous formulations, making it possible to administer high-concentration biologics. The device reduces the required injection force by up to 99%, allowing for self-administration of medication and vaccines in remote areas.
Researchers successfully inhibited the P2X4 receptor, which plays a significant role in post-stroke damage and recovery. The study shows that short-term inhibition of this receptor can regulate immune cell activation and improve both acute and chronic stroke recovery.
A new study has identified a better treatment option for arteriovenous fistulas used in hemodialysis, reducing the need for repeated hospital visits and procedures. The drug-coated balloon angioplasty treatment has shown promising results, with patients being 25% more likely to have a functioning access point after 6 months.
Research highlights the link between Alport syndrome genotype and treatment effectiveness with ACE inhibitors and RAS blockers, showing varied responses to treatment depending on mutation type and age of progression to end-stage kidney disease.
Researchers identified a small protein that mobilizes bone resorbing cells under osteoporotic conditions. Chemical inhibitors targeting this protein show promise in blocking bone resorption without disrupting normal bone turnover.
Patients with severe COVID-19 symptoms showed improved outcomes when administered Interleukin-6 (IL6ri) inhibitors, such as sarilumab or tocilizumab, earlier in the disease course. This reduced mortality rates and the need for intubation, with a higher discharge rate among those treated early.
Patients who had previously suffered a vertebral fracture experienced an increased risk of major osteoporotic fractures after longer bisphosphonate drug holidays. The study suggests that these breaks may lead to a partial loss of protective effects against fractures, highlighting the need for individualized management decisions.
A randomized clinical trial found that prescribed doses of non-intoxicating CBD reduced cannabis use and increased abstinence days. Participants treated with 400mg or 800mg CBD showed lower levels of cannabis in their urine and more days abstinent compared to placebo.
Wolfram Syndrome is a progressive degenerative disease characterized by diabetes, psychiatric symptoms, loss of vision, deafness, and incontinence. Yale researchers have discovered a potential treatment involving two existing drugs that restore calcium signaling and improve cell functions.
A single dose of the drug tocilizumab was found to reduce mortality by 45% and increase the likelihood of patients leaving the hospital or being off a ventilator within a month. However, this benefit came with an increased risk of additional infection.
A new nanoconjugate has been developed to target and kill acute myeloid leukemia tumor cells without harming healthy ones. The nanoparticle is specifically designed to bind to the CXCR4 receptor, which is overexpressed in leukemic cells, and deliver a potent toxin that kills the cancer cells.
Researchers have developed a novel immunotherapy using genetically modified natural killer cells to target and kill cancer cells in glioblastoma multiforme, a highly aggressive brain tumor. The treatment approach has shown high efficiency and is considered safer than other cell-based therapies.
Scientists have discovered a new approach to treating Pelizaeus-Merzbacher disease by targeting toxic proteins that prevent myelin production. The treatment, which uses antisense oligonucleotides, reduced symptoms and extended lifespan in laboratory studies.
A five-year outcomes study of 30 patients found that early-stage deep brain stimulation (DBS) decreased the risk of disease progression and polypharmacy compared to optimal medical therapy alone. The study showed significant improvements in motor symptoms, with DBS patients requiring less medication for symptom management.
Researchers have developed eye drops that target caspase-9 enzyme to treat retinal vein occlusion, a common cause of blindness. The treatment has shown promise in improving retinal function and reducing swelling in a mouse model of the condition.
A new study reveals that the enzyme SAMHD1 protects B-ALL cells from nelarabine's anti-cancer effects, but not T-ALL cells. This discovery has crucial implications for leukaemia treatment, offering a potential biomarker to tailor therapy to individual patient needs.
The USPSTF recommends screening for unhealthy drug use in adults 18 or older to prevent fatal overdoses, injuries, and disability. The recommendation replaces the 2008 statement finding insufficient evidence, citing a significant cause of preventable death in 2017.
Researchers at the University of Cincinnati have found that a combination therapy using SapC-DOPS nanovesicles and standard chemotherapy may improve outcomes for patients with pancreatic cancer. The study suggests that this approach could potentially extend lives and provide hope to patients with limited treatment options.
Researchers estimated appropriate pediatric-specific dosing regimens for hydroxychloroquine and remdesivir to treat pediatric patients with COVID-19. The study suggests these treatments may be effective for children infected with the virus.
Acalabrutinib improved oxygenation levels and decreased molecular markers of inflammation in most patients with severe COVID-19. The treatment showed promise in reducing the severity of the disease, particularly among those on mechanical ventilation.
A study published in Oncotarget found that T-DM1 significantly improves response rates and median progression-free survival in patients with HER2 positive metastatic breast cancer. This suggests a preferred second-line choice for T-DM1 over trastuzumab emtansine.
Scientists have developed a new treatment to reduce swelling after brain and spinal cord injuries, offering hope to 75 million victims worldwide. The breakthrough uses the already-licensed anti-psychotic medicine trifluoperazine to alter aquaporin behaviour in cells, preventing cell swelling and pressure build-up.
A new study published in the Canadian Journal of Cardiology suggests that women's treatment decisions during pregnancy should be tailored to their individual values and preferences. The research found that half of the women preferred tight control of blood pressure, while half preferred less-tight control, with Caucasian ethnicity, uni...
A new study found that methylene blue reduces tissue damage, inflammation, and degree of necrosis in intestinal ischemia-reperfusion. The drug also improves heart rate and blood pressure in animals.
Patients receiving 177Lu-DOTATATE radiation therapy may experience travel delays at U.S. ports of entry due to residual radiation activity; carrying a travel card with treatment information can help alleviate this issue.
A new study reveals an alarming treatment gap for fragility fractures in six European countries, resulting in estimated annual costs of €37.5 billion in 2017, which is expected to increase by 23% to €47.4 billion by 2030.
A new drug delivery method using light-activated vitamin B12 molecules could reduce whole-body side effects from rheumatoid arthritis treatments. The approach decreases arthritis symptoms while carrying and delivering much lower quantities of the medication.
A new study by University of Copenhagen researchers shows that administering nimodipine, an already approved drug for high blood pressure, can prevent the development of spasticity after spinal cord injuries. The effect is long-lasting and continues even after treatment has stopped.
Researchers developed a mathematical model that forecasts patient responses to intermittent androgen deprivation therapy based on changing levels of the biomarker PSA. The model predicted 89% accuracy in developing patient resistance, enabling personalized treatment options.
A mindfulness app training program reduced physician anxiety by 57% and emotional exhaustion by 20%, suggesting its potential to treat burnout as well. The study's findings support the use of digital therapeutics like apps-based treatments for low-cost, widely disseminated interventions.
According to an analysis of patient forums, desiccated thyroid extract (DTE) is more effective than other thyroid hormone medications for improving symptoms and overall well-being. The treatment, also known as nature thyroid or Armour thyroid, has been used by 10%-25% of people with hypothyroidism.
Vericiguat, a novel guanylate cyclase stimulator agent, has shown significant benefits in reducing negative health events in patients with worsening chronic heart failure. The VICTORIA trial demonstrated an absolute reduction of 4.2% in patients already receiving optimal care.
Aarhus University researcher Ulf Simonsen is developing a treatment with Senicapoc to reduce severe lung damage and need for ventilators in COVID-19 patients. The project aims to assess the effect within two months.
A clinical trial found that electrical stimulation improved symptoms in 53% of women with constipation, with lasting benefits for at least 3 months. The treatment was well-tolerated and offered a promising alternative to laxative medications.
A new compound has been discovered that targets a pathway causing brain swelling after stroke, potentially reducing cases of brain injury and death. The compound, called ZT-1a, was tested on mice and rats with stroke or hydrocephalus and showed promise in effectively reducing brain swelling.
A study published in Journal of the American Academy of Child and Adolescent Psychiatry found that stepwise treatment for pediatric OCD results in excellent long-term stability of treatment gains. Most participants responded well to treatment, with significant improvements in symptoms, psychosocial functioning, and depressive symptoms.
A UK clinical trial has found an effective intervention to increase hepatitis C testing and treatment in primary care. The HepCATT study increased HCV testing by 59% and treatment assessments by five times in intervention practices compared to control.
Treating stroke patients in mobile stroke units speeds up treatment and reduces disability. The Berlin Prehospital Or Usual Delivery trial found that prehospital treatment in a mobile stroke unit improved patient outcomes compared to usual care.
Researchers identify precise receptor chain involved in atopic dermatitis, a condition marked by chronic inflammation and itchy patches of skin. A novel antibody targeting this receptor may serve as a potential therapeutic treatment for the disease.
Scientists have discovered a novel gold nanocluster that can inhibit Aβ monomer formation, dissolve preformed fibrils and restore conformation of peptides. The nanocluster also has good biocompatibility and infiltration ability across the blood-brain barrier.
Researchers at Moffitt Cancer Center present a case study of an adaptive treatment approach based on evolutionary principles in prostate cancer, suggesting it as a promising alternative to traditional treatments. The approach involves forcing tumors into repeatable treatment cycles, which may limit the development of uncontrollable dru...
A Stony Brook University-led study finds that early intervention in schizophrenia does not improve long-term outcomes, contradicting common views. Comprehensive care has been shown to reduce symptoms and improve mental health, but treatment effects may be overstated due to lead-time bias.
Researchers found that a new stimulation treatment increased blood flow to the brain and improved hand strength in patients with minor strokes. The treatment also showed promise in decreasing disability in patients with severe stroke, regardless of age, sex, or severity of symptoms.
Eternygen presents preclinical study data demonstrating INDY inhibition reverses nonalcoholic steatohepatitis (NASH) in a diet-induced mouse model. The treatment also reduces liver injury and inflammation.
Scientists have made an important discovery that could lead to more effective treatments for people living with multiple sclerosis (MS). The study found that drugs targeting the IL-17 molecule may not need to get across the blood-brain-barrier to be effective in treating MS.
Recent clinical trials of Prolonged Exposure Therapy and Cognitive Processing Therapy show limited effectiveness in treating active duty military personnel and veterans with PTSD. The studies suggest that emotionally demanding therapies may not be beneficial for all patients, and more personalized treatment approaches are needed to acc...
The guideline provides a framework for diagnosing and treating complex ADHD in children and adolescents, emphasizing the importance of psychosocial interventions to improve function. Key action statements include comprehensive assessment, behavioral and educational interventions, and monitoring throughout life.
Chronic lymphocytic leukemia (CLL) patients respond differently to ibrutinib treatment due to individual genetic and epigenetic profiles. The study reveals a shared genetic program in CLL cells responding to ibrutinib, but with patient-specific execution, leading to varying disease progression rates.
Scientists have obtained a high-resolution view of glucagon-like peptide-1 receptors (GLP1R), which play a crucial role in regulating blood sugar levels. The study provides new insights into GLP1R function and its potential as a target for treating conditions like type 2 diabetes.
A novel pharmacological chaperone has been shown to restore levels of the sorting molecule VPS35 and prevent the accumulation of abnormal proteins in mice with Alzheimer's disease. This treatment approach has been proven to improve memory and learning, reducing tau tangles and amyloid-beta plaques.
Researchers found that psychedelic drug users experience increased positive mood, social connectedness, and transformative experiences at mass gatherings. The study validates previous findings in laboratory and clinical settings, suggesting potential therapeutic effects of psychedelic use.
Antimalarial drugs are found to work against each other when combined, a phenomenon known as antagonistic cooperation. This discovery could lead to more effective treatments for malaria, a disease that killed 435,000 people in 2017.
A UCLA-led study found that family-focused therapy can delay new and recurring bipolar symptoms in children and teens. The treatment, which involves teaching patients and families better communication skills, resulted in 77% of adolescents recovering from initial symptoms within four years.
Researchers at the University of Dundee are working on a new effort to tackle tuberculosis, identifying new treatment options for the disease. With a $3 million grant from the Bill & Melinda Gates Foundation, they aim to improve drug discovery and develop new candidate drugs to treat TB.
Researchers at Uppsala University used a computer algorithm to identify a promising new treatment for neuroblastoma, a form of childhood cancer. The new treatment targets the CNR2 receptor protein, which was discovered using massive amounts of genetic and pharmacological data.
A systematic review and meta-analysis found insufficient evidence to determine whether serotonin reuptake inhibitors or trauma-focused psychotherapy are more effective in treating PTSD. The study concludes that clinicians should make shared decisions with patients based on patient preferences regarding treatment characteristics.
A new drug trial by Monash University Professor Eric Morand shows a statistically-significant reduction in disease activity versus placebo in lupus patients. The TULIP 2 trial found a significant effect in global disease activity measures, including improved skin disease and reduced steroid doses.
A Baylor University researcher has developed a new tool, the Treatment Adherence Perception Questionnaire (TAPQ), to help patients adhere to their treatment plans. The TAPQ assesses two key attitudes: perceived benefit and perceived burden, which are strongly associated with motivation to adhere to treatment.